

CITATION REPORT

List of articles citing

Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issues

DOI: 10.1101/2022.06.02.22275920

»»»

Source: <https://exaly.com/paper-pdf/146277730/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists. 2022 , 14, 3775		0
3	Co-agonist therapeutics come of age for obesity.		1
2	An update on peptide-based therapies for type 2 diabetes and obesity. 2023 , 161, 170939		2
1	The molecular pharmacology of glucagon agonists in diabetes and obesity. 2023 , 165, 171003		0